Novartis Pullback Fuels Doubts on Novel CAR-T Cancer Therapy

  • Juno, Kite drop after Novartis’s move to fold unit, cut jobs
  • ‘Data on CAR-T has never been better,’ Juno CEO says

Novartis AG’s decision to fold a unit that was working on a novel cancer therapy casts doubt on other companies that are betting on what’s seen as one of the most exciting approaches to fighting the disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.